Intercept Pharmaceuticals (ICPT) Stock Price Down 8.2%

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) shares traded down 8.2% during trading on Thursday . The stock traded as low as $53.25 and last traded at $53.29. 1,266,062 shares changed hands during mid-day trading, an increase of 14% from the average session volume of 1,109,358 shares. The stock had previously closed at $58.08.

Several research analysts have recently commented on the company. Wedbush reissued a “buy” rating and issued a $253.00 price target on shares of Intercept Pharmaceuticals in a research report on Friday, December 22nd. ValuEngine downgraded Intercept Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. BidaskClub upgraded Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, January 25th. Leerink Swann restated a “hold” rating and set a $60.00 target price on shares of Intercept Pharmaceuticals in a research note on Tuesday, November 28th. Finally, Oppenheimer restated a “hold” rating on shares of Intercept Pharmaceuticals in a research note on Monday, January 29th. Five investment analysts have rated the stock with a sell rating, ten have given a hold rating and ten have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $134.86.

The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 3.15.

A number of institutional investors have recently bought and sold shares of ICPT. WFG Advisors LP grew its stake in Intercept Pharmaceuticals by 16.4% during the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 125 shares during the last quarter. IFP Advisors Inc grew its stake in Intercept Pharmaceuticals by 90.9% during the 3rd quarter. IFP Advisors Inc now owns 2,482 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 1,182 shares during the last quarter. Birchview Capital LP purchased a new stake in Intercept Pharmaceuticals during the 3rd quarter valued at about $250,000. Oppenheimer & Co. Inc. grew its stake in Intercept Pharmaceuticals by 145.1% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 4,785 shares of the biopharmaceutical company’s stock valued at $278,000 after purchasing an additional 2,833 shares during the last quarter. Finally, Exane Derivatives grew its stake in Intercept Pharmaceuticals by 46,054.5% during the 3rd quarter. Exane Derivatives now owns 5,077 shares of the biopharmaceutical company’s stock valued at $295,000 after purchasing an additional 5,066 shares during the last quarter. Institutional investors and hedge funds own 74.37% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Intercept Pharmaceuticals (ICPT) Stock Price Down 8.2%” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://sportsperspectives.com/2018/02/09/intercept-pharmaceuticals-icpt-stock-price-down-8-2.html.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply